Brazil's SaMD Shake-Up: A Pure Global Guide to ANVISA's New Digital Health Rules.

This week, we dive into a critical regulatory shift in Latin America's largest MedTech market. Brazil's ANVISA has just issued new, stringent guidelines for Software as a Medical Device (SaMD), specifically targeting the booming field of AI-powered diagnostics. This update reshapes the pathway to market for innovators both inside and outside Brazil. We break down exactly what has changed, focusing on the new risk classifications and the intensified requirements for local clinical data. This episode is essential for any MedTech manufacturer, investor, or regulatory professional looking to understand the evolving landscape in Brazil and what it takes to succeed there now. **Case Study Spotlight:** Imagine your company has an innovative AI tool for detecting diabetic retinopathy, ready for Brazilian launch with a Class II strategy. Suddenly, new ANVISA guidance reclassifies your product to high-risk Class III, demanding extensive local clinical trials and delaying your launch by over a year. We discuss the strategic pivot required to overcome this exact challenge. **In this episode, you will learn:** - What are the key differences in ANVISA's new SaMD classification system for AI? - How do the new Brazilian guidelines align with international standards like the EU MDR? - What specific clinical evidence is now required for a high-risk SaMD submission in Brazil? - Does this new framework create more barriers or opportunities for foreign developers? - What are the most common pitfalls to avoid when submitting your AI SaMD for approval under the new rules? - How can you leverage existing global data while satisfying the new local requirements? - What does this mean for the future of digital health investment in Latin America? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI to streamline market access in complex, evolving markets like Brazil. Facing challenges with the new SaMD regulations? Contact Pure Global at [email protected] or visit us at https://pureglobal.com/ for a strategic consultation.